How LeMaitre Vascular Inc (LMAT) Stacks Up Against Its Peers

As industry-wide interest jumped, key money managers have jumped into LeMaitre Vascular Inc (NASDAQ:LMAT) headfirst. Arrowstreet Capital, led by Peter Rathjens, Bruce Clarke and John Campbell, created the most outsized position in LeMaitre Vascular Inc (NASDAQ:LMAT). Arrowstreet Capital had $0.8 million invested in the company at the end of the quarter. David E. Shaw’s D E Shaw also made a $0.6 million investment in the stock during the quarter. The other funds with new positions in the stock are Ken Griffin’s Citadel Investment Group and Neil Chriss’ Hutchin Hill Capital.

Let’s now take a look at hedge fund activity in other stocks similar to LeMaitre Vascular Inc (NASDAQ:LMAT). We will take a look at Culp, Inc. (NYSE:CFI), Spok Holdings Inc (NASDAQ:SPOK), Cytokinetics, Inc. (NASDAQ:CYTK), and Dynex Capital Inc (NYSE:DX). This group of stocks’ market caps match LMAT’s market cap.

As you can see these stocks had an average of 9 hedge funds with bullish positions and the average amount invested in these stocks was $39 million. That figure was $29 million in LMAT’s case. Cytokinetics, Inc. (NASDAQ:CYTK) is the most popular stock in this table. On the other hand Spok Holdings Inc (NASDAQ:SPOK) is the least popular one with only 5 bullish hedge fund positions. LeMaitre Vascular Inc (NASDAQ:LMAT) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard CYTK might be a better candidate to consider taking a long position in.

Disclosure: None